Tag: KDC-MN-1648

  • Iclepertin

    Selective glycine transporter type 1 (GlyT1) inhibitor for glutamatergic NMDA receptor enhancement

    A potent azabicyclo[3.1.0]hexane methanone GlyT1 inhibitor developed by Boehringer Ingelheim to normalize glutamatergic hypofunction in schizophrenia, distinguished by positive Phase II cognitive efficacy signals (standardized effect size 0.34 on MCCB at 10 mg) and subsequent failure to replicate in the 1835-patient Phase III CONNEX programme.

    Abstract

    Iclepertin (BI 425809) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) with an IC50 of 5.0 nanomolar in human SK-N-MC cells, developed by Boehringer Ingelheim for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound is an orally bioavailable azabicyclo[3.1.0]hexane methanone bearing two trifluoromethyl groups and a methylsulfonyl substituent, with three defined stereocenters and a molecular weight of 512.42 g/mol. By blocking the reuptake of glycine from the synaptic cleft into astrocytes and presynaptic terminals, iclepertin increases synaptic glycine concentration at the glycine-B co-agonist site of the N-methyl-D-aspartate (NMDA) receptor, thereby enhancing glutamatergic neurotransmission. This mechanism addresses the NMDA receptor hypofunction hypothesis of schizophrenia, which posits that reduced glutamatergic signaling contributes to the cognitive deficits observed in the disorder.

    Pharmacokinetically, iclepertin exhibits a terminal half-life of 34 to 59 hours, supporting once-daily oral dosing with steady-state conditions achieved by day 6. The compound is metabolized predominantly (90 percent or greater) by cytochrome P450 3A4, rendering it sensitive to strong CYP3A4 inhibitors (approximately 6-fold AUC increase with itraconazole) and inducers (approximately 90 percent AUC reduction with rifampicin).

    The Phase II clinical programme produced divergent results across indications. However, a parallel 610-patient Phase II trial in mild-to-moderate Alzheimer’s disease dementia (NCT02788513) failed to demonstrate any dose-response relationship on the ADAS-Cog11 primary endpoint. A subsequent Phase II trial combining iclepertin with computerized cognitive training (NCT03859973, n=200) also failed to meet its primary endpoint. The compound received United States Food and Drug Administration Breakthrough Therapy Designation for CIAS in May 2021. Iclepertin was well tolerated across all trials, with adverse event rates numerically similar to or lower than placebo. The compound is not approved in any jurisdiction.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.